Skip to content
Open access

A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity.

Nov 2026 · Cancer Cell · Vol 44 11, pp. 2227-2248.e21 · 0 citations · 83 references
Medicine

Abstract

Transforming growth factor β (TGF-β) accumulation in the tumor microenvironment (TME) is a major barrier to durable antitumor immunity. We developed fibronectin extra domain B (FN-EDB)-binding peptide (FEBP)-soluble TβRII-Fc (sTβRII), an engineered inhibitor targeting the FN-EDB-rich tumor matrix for localized TGF-β blockade. In fibrotic, immune-excluded tumors, FEBP-sTβRII suppresses TGF-β/SMAD signaling to unleash T cell activation and IFN-γ production, thereby driving feedforward cancer-associated fibroblast (CAF)-myeloid reprogramming toward an antigen-presenting state. This coordinated remodeling relieves immune exclusion and converts the fibrotic TME into an antigen-visible ecosystem that sustains robust T cell infiltration and activation. Consequently, FEBP-sTβRII induces T cell-dependent tumor regression, expands effector-memory populations, and elicits long-term, cross-protective antitumor immunity, while minimizing peripheral transcriptional disturbances compared with systemic sTβRII. Together, these findings show that spatially targeted TGF-β blockade overcomes fibrotic immune exclusion to establish durable local and systemic tumor immunity.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.